GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » American Oncology Network Inc (NAS:AONCW) » Definitions » Total Stockholders Equity

American Oncology Network (American Oncology Network) Total Stockholders Equity : $-102.46 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is American Oncology Network Total Stockholders Equity?

American Oncology Network's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-102.46 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. American Oncology Network's Book Value per Share for the quarter that ended in Mar. 2024 was $N/A. The ratio of a company's debt over equity can be used to measure how leveraged this company is. American Oncology Network's Debt-to-Equity for the quarter that ended in Mar. 2024 was -1.25.

American Oncology Network Total Stockholders Equity Historical Data

The historical data trend for American Oncology Network's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Oncology Network Total Stockholders Equity Chart

American Oncology Network Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
- 59.54 62.02 -96.74

American Oncology Network Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Total Stockholders Equity Get a 7-Day Free Trial 62.02 - -276.35 -96.74 -102.46

American Oncology Network  (NAS:AONCW) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

American Oncology Network's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-102.46-64.986)/0
=N/A

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

American Oncology Network's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(7.92 + 120.642) / -102.46
=-1.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

American Oncology Network Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of American Oncology Network's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

American Oncology Network (American Oncology Network) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » American Oncology Network Inc (NAS:AONCW) » Definitions » Total Stockholders Equity
Comparable Companies
PIII TOI BTMD AVAH CYH JYNT PNTG SNDA AIRS CCM HCA SAU:4013 SZSE:300015 HKSE:06618 XTER:FRE BKK:BDMS XKLS:5225 BSP:RDOR3 XTER:FME UHS
Traded in Other Exchanges
AONC:USA
Address
10485 NE 6th Street, Unit 3930, Bellevue, WA, USA, 98004
Website
https://www.aoncology.com
American Oncology Network Inc Formerly American Oncology Network LLC is an alliance of physicians and seasoned healthcare leaders who provide comprehensive oncology services through 24 oncology practices located in Arkansas, Louisiana, Indiana, Virginia, Ohio, Nevada, Iowa, Missouri, Washington, North Carolina, Michigan, Maryland, South Carolina, Arizona, and Georgia. The Company also provides expertise in drug procurement and payor contracting, along with practice diversification through centralized laboratory and pathology services, as well as specialty pharmacy services.